Dimethyl Sulfoxide
Apexbio Technology LLC BMX-IN-1(Synonyms: BMX Kinase Inhibitor, ETK kinase inhibitor, BMX-IN1, BMX inhibitor, ETK inhibitor), 10mM (in 1mL DMSO), CAS: 1431525-23-3.
BMX-IN-1 (CAS 1431525-23-3) is a highly selective irreversible inhibitor targeting BMX (bone marrow kinase on chromosome X also known as ETK) a member of the Tec tyrosine kinase family BMX is prominently expressed in arterial endothelium and myeloid hematopoietic cells functioning in ischemia-induced arterial and lymphatic vessel formation processes and contributing to tumor growth In cellular models expressing Tel-BMX fusion proteins BMX-IN-1 treatment at low doses effectively reduces proliferation highlighting its potential utility in cancer research particularly prostate cancer studies
Apexbio Technology LLC VX-661(Synonyms: Tezacaftor, VX661, VX-661, VX 661), 10mM (in 1mL DMSO), CAS: 1152311-62-0.
VX-661 (CAS 1152311-62-0) is a small-molecule CFTR corrector developed by Vertex Pharmaceuticals designed to restore trafficking and enhance cellular surface expression of the mutated F508del-CFTR protein By facilitating proper folding and transport of this commonly mutated cystic fibrosis transmembrane conductance regulator (CFTR) VX-661 increases CFTR-mediated chloride channel activity in vitro Preclinical and clinical research have explored VX-661 alone and in combination with ivacaftor demonstrating enhanced F508del-CFTR functionality and providing a promising strategy for addressing cystic fibrosis caused by the F508del mutation
Apexbio Technology LLC BML-210(CAY10433) 537034-17-6 10mM (in 1mL DMSO)
BML-210 (CAY10433 CAS 537034-17-6) is a small molecule inhibitor targeting histone deacetylases (HDACs) enzymes responsible for removing acetyl groups from lysine residues on histone proteins leading to chromatin compaction and transcriptional repression BML-210 demonstrates HDAC inhibitory activity with an IC50 of 87 M In cellular assays this compound increases FXN mRNA expression and histone H4 acetylation induces G1 cell cycle arrest and apoptosis and enhances erythroid and granulocytic differentiation in human leukemia cell lines (K562 HL-60) BML-210 is utilized in research investigating epigenetic modulation leukemia biology and gene regulation mechanisms
Apexbio Technology LLC Ornidazole 16773-42-5 10mM (in 1mL DMSO)
Ornidazole a 5-nitroimidazole derivative exhibits antibacterial and antiprotozoal activities by interfering with DNA synthesis in anaerobic microorganisms through the reduction of its nitro group forming cytotoxic intermediates In experimental assays Ornidazole demonstrates inhibitory activity against diverse anaerobic bacterial strains including Bacteroides and Clostridium species and protozoan pathogens such as Giardia lamblia and Trichomonas vaginalis typically showing IC50 values ranging from micromolar to low millimolar concentrations This compound is widely utilized in microbiology and infectious disease research to elucidate anaerobic microbial drug sensitivity pathogen resistance mechanisms and protozoan infection biology
Apexbio Technology LLC Ki16198 355025-13-7 10mM (in 1mL DMSO)
Ki16198 (CAS 355025-13-7) is the methyl ester derivative of Ki16425 and functions as an antagonist of lysophosphatidic acid (LPA) receptors preferentially inhibiting LPA1 and LPA3 receptor subtypes Ki16198 reduces receptor-mediated inositol phosphate production with Ki values of 0 34 M (LPA1) and 0 93 M (LPA3) showing minimal inhibition of LPA2 and no significant activity against LPA4 6 In vitro Ki16198 attenuates LPA-induced proliferation migration invasion and proMMP-9 expression in cancer cells In vivo studies report suppression of pancreatic tumor growth metastasis and ascites formation highlighting its utility in investigating LPA-related cancer progression pathways
Apexbio Technology LLC AdipoRon 924416-43-3 10mM (in 1mL DMSO)
AdipoRon (CAS 924416-43-3) is an agonist of adiponectin receptors AdipoR1 and AdipoR2 displaying binding affinities (Kd) of 1 8 M and 3 1 M respectively Upon receptor activation it promotes phosphorylation of AMPK via AdipoR1 and upregulates expression of PGC-1 improving mitochondrial biogenesis in muscle cell models In vivo studies show that AdipoRon administration stimulates AMPK and PPAR- signaling in liver and muscle tissues subsequently reducing circulating glucose insulin triglycerides and inflammatory cytokines This compound is employed in metabolic and cardiovascular disease research especially regarding insulin resistance dyslipidemia obesity-related inflammation and ischemia-induced myocardial damage
Apexbio Technology LLC Teriflunomide 108605-62-5 10mM (in 1mL DMSO)
Teriflunomide (CAS 108605-62-5) the active metabolite of the antirheumatic agent Leflunomide acts primarily by selectively inhibiting dihydroorotate dehydrogenase (DHODH) a mitochondrial enzyme critical for pyrimidine nucleotide synthesis By restricting pyrimidine production teriflunomide exerts antiproliferative effects on activated lymphocytes resulting in immunosuppressive and anti-inflammatory activity Due to these properties teriflunomide is extensively studied as an oral therapeutic candidate in multiple sclerosis research addressing autoimmune-mediated disorders
Apexbio Technology LLC SU11274 658084-23-2 10mM (in 1mL DMSO)
SU11274 (CAS 658084-23-2) is a selective inhibitor targeting Met kinase exhibiting an IC50 of approximately 10 nM The compound specifically suppresses the autophosphorylation of Met at residues Tyr1234/1235 disrupting receptor activity with minimal effects on other receptor tyrosine kinases such as EGFR and PDGFR or serine/threonine kinases including CDK2 In NIH3T3 cells expressing drug-sensitive or resistant MET mutants and in H1993 human lung cancer cells treatment with SU11274 induces a dose-dependent inhibition of Met phosphorylation and impairs receptor ubiquitination leading to receptor accumulation SU11274 serves as a useful tool for investigating Met signaling pathways in oncology research
Apexbio Technology LLC Ponatinib (AP24534) 943319-70-8 10mM (in 1mL DMSO)
Ponatinib (AP24534 CAS 943319-70-8) is a second-generation small molecule inhibitor targeting the BCR-ABL fusion kinase The BCR-ABL fusion arising from a t(9 22) chromosomal translocation encodes oncogenic tyrosine kinase variants implicated in chronic myeloid leukemia (CML) acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) Ponatinib inhibits both wild-type BCR-ABL (IC50 0 5 nM) and resistant mutants notably the T315I mutant (IC50 11 nM) Additionally it potently inhibits clinically relevant kinases such as RET FLT3 KIT PDGFR / and FGFR1 Ponatinib is utilized in cancer biology research pertaining to kinase-driven malignancies
Apexbio Technology LLC Ciprofibrate 52214-84-3 10mM (in 1mL DMSO)
Ciprofibrate is a selective agonist targeting peroxisome proliferator-activated receptor alpha (PPAR ) a nuclear receptor involved in regulating lipid metabolism and energy homeostasis Its activation promotes gene expression linked to fatty acid oxidation triglyceride reduction and cholesterol metabolism Ciprofibrate is frequently applied as a molecular tool in biomedical research to investigate mechanisms underlying dyslipidemia atherosclerosis and metabolic-related disorders Additionally due to its receptor-specific mode of action it serves as a standard experimental reference in in vitro assays and animal models assessing lipid-lowering therapeutic strategies and PPAR -dependent signaling pathways
Apexbio Technology LLC Ticagrelor 274693-27-5 10mM (in 1mL DMSO)
Ticagrelor (CAS 274693-27-5) is an orally active reversible antagonist targeting the platelet P2Y12 receptor By competitively binding to P2Y12 ticagrelor inhibits ADP-mediated platelet aggregation resulting in dose-dependent suppression of platelet activation and thrombosis in vitro Unlike other P2Y12 inhibitors requiring metabolic activation ticagrelor acts without metabolic transformation though it is primarily metabolized by CYP3A4 and CYP2C19 enzymes This compound is frequently employed in biomedical research exploring platelet function thrombosis mechanisms and drug-drug interactions involving cytochrome P450 enzymes
Apexbio Technology LLC Topotecan 123948-87-8 10mM (in 1mL DMSO)
Topotecan (CAS 123948-87-8) a semisynthetic derivative of camptothecin functions by selectively inhibiting topoisomerase I This inhibition stabilizes enzyme-DNA cleavage complexes disrupting DNA replication and transcription processes essential for tumor cell proliferation In preclinical studies topotecan demonstrated antitumor activity in mouse models of leukemia (P388) Lewis lung carcinoma B16 melanoma and human colon adenocarcinoma xenograft HT-29 Its toxicity primarily affecting rapidly proliferating tissues such as bone marrow and gastrointestinal epithelium was concentration-dependent and reversible Topotecan is employed extensively as a research tool in oncology studies focusing on DNA-topoisomerase interactions and targeting solid tumor growth
Apexbio Technology LLC JIB-04 199596-05-9 10mM (in 1mL DMSO)
JIB-04 (CAS 199596-05-9) is a selective small-molecule inhibitor targeting Jumonji histone demethylases specifically suppressing enzymes including JARID1A JMJD2 family members (JMJD2A-E) and JMJD3 Structurally categorized as a pyridine hydrazone derivative JIB-04 inhibits demethylase activity independently of competitive binding with -ketoglutarate In vitro assays revealed IC50 values ranging from 230 nM to 1100 nM across various Jumonji enzymes Additionally JIB-04 demonstrates preferential inhibition of cancer cell proliferation versus normal cells notably in lung and prostate cancer cell lines and effectively reduces tumor growth in mouse xenograft models highlighting its relevance for cancer research
Apexbio Technology LLC Ro 3306 872573-93-8 10mM (in 1mL DMSO)
Ro 3306 (CAS 872573-93-8) is an ATP-competitive inhibitor targeting cyclin-dependent kinase 1 (CDK1) It selectively inhibits CDK1/cyclin B1 and CDK1/cyclin A complexes (Ki values of 35 nM and 110 nM respectively) thereby interfering with mitotic entry In DU145 cells Ro 3306 at 1 M diminishes BRCA1 localization at DNA double-strand breaks and suppresses RAD51 foci formation sensitizing these cells to DNA-damaging agents such as AZ12253801 Hence Ro 3306 is useful in studying cell cycle regulation DNA repair mechanisms and sensitization of cancer cells to targeted therapies